Innovating Works

AELIX THERAPEUTICS

Activa
MISTRAL: Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA tramitó un H2020: The HIV/AIDS pandemic continues to be one of the major health challenges ever faced by mankind. Far from being resolved, HIV is soaring in Eastern Europe (60% increase in new infections and 27% increa...
2020-01-01 | Financiado
RTC-2017-6473-1: DESARROLLO DE UNA NUEVA VACUNA TERAPÉUTICA CONTRA EL VIH (NUVATERA) AELIX THERAPEUTICS tramitó un AEI: Según ONUSIDA en 2016 36,7 millones de personas viven con VIH en el mundo, con cerca de 1,8 millones de nuevas infecciones y un millón de muertes relacionadas, En España se producen 4,000 nuevas infec...
2018-01-01 | Financiado
HIVACAR: Evaluating a Combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection CONSORCI INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER tramitó un H2020: The main goal of HIVACAR proposal is to change the current paradigm of HIV treatment by obtaining a functional cure for HIV (i.e., control of viral load to levels below the threshold of 50 copies/ml a...
2017-01-01 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.